ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has licensed one of its pluripotent cell lines to Goliver ...

ALAMEDA, Calif.--(BUSINESS WIRE)--BioTime, Inc. (NYSE American and TASE: BTX), a clinical-stage biotechnology company developing novel cell therapies for unmet medical needs, today announced it is ...

ALAMEDA, Calif.--BioTime, Inc. (NYSE MKT: BTX), today announced that it has initiated the development of two new products based on its HyStem® hydrogel technology platform. The first of these new ...

BioTime, Inc. (NYSE MKT: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced the signing of an exclusive sublicense agreement and a ...

BioTime, Inc. (NYSE: BTX) is a clinical-stage biotechnology company focused on regenerative medicine and pluripotent stem cell technologies. It was established by Dr. Michael D. West, the original ...

BioTime (BTX) appears an attractive pick, as it has been recently upgraded to a Zacks Rank #1 (Strong Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the ...

On August 2, 2018, BioTime Inc. (NYSE: BTX; $2.31; market capitalization: $293 million) announced results for 2Q18. BioTime primary clinical programs Renevia and OpRegen progressed on research and ...

Discovery from The Wistar Institute covers the SP100 gene. BioTime obtained an exclusive license from The Wistar Institute for technology related to a gene called SP100 implicated in cancer and stem ...

Dr. Michael D. West, Ph.D., is the Chief Executive Officer of BioTime, Inc., of Alameda, Calif., as well as its subsidiaries. The companies are focused on developing an array of research and ...

Geron's stem cell assets were given a new lease in early January when former CEO Tom Okarma, now heading a subsidiary of BioTime of Alameda, California, signed a definitive agreement for the latter to ...